Marqeta Inc vs Nuwellis Inc — how do they compare? Marqeta Inc trades at $15.52 (market cap $1.62B), while Nuwellis Inc trades at $1.48 (market cap $522.76K). The key difference: Marqeta Inc is far larger — about 3098.9× Nuwellis Inc's market cap. Which is the better fit depends on your goals.
| MQ | NUWE | |
|---|---|---|
Market Cap | $1.62B | $522.76K |
Sector | Technology | Technology |
52-Week High | $26.00 | $220.50 |
52-Week Low | $15.04 | $1.42 |
Enterprise Value | $939.53M | -$1.29M |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
NUWE trades at $1.49, down 8.59% over the past day, with a bearish technical outlook. The company reported a net loss of $17.52M in 2025, with a negative net income margin of -217.22%, though it has shown revenue growth and recent strategic expansions in pediatric care. A recent 35:1 reverse stock split was executed on June 26, 2026.
The outlook remains high-risk due to persistent losses and cash burn, but growth initiatives and new product development offer potential. Key risks include execution challenges and dependence on financing. Analyst sentiment is mixed, with a 50% buy and 50% hold rating among covered analysts.
Trailing returns across standard periods
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →